arrow
H

Haixia Zhou

Jiangsu Institute of Hematology
H指数:21
被引数:2,360

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A phase 2 trial of a “sandwich” strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic leukemia

一项“夹心”策略的2期临床试验:序贯CD22/CD19嵌合抗原受体T细胞疗法联合自体造血干细胞移植治疗费城染色体阴性B细胞急性淋巴细胞白血病患者

Cancer
IF5.1
2025-11-060
OAAI
IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial

IL-6基因敲低抗CD19 CAR-T细胞(ssCART-19)用于复发或难治性急性淋巴细胞白血病患者的I期临床试验

2025-10-270
OA
Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90a

Irisin通过其整合素受体在涉及细胞外Hsp90a的两步过程中发挥作用

2023-06-0119
OAAI